Interleukin-20 receptor type II (IL-20R type II) (IL-20R type II)

The Interleukin-20 receptor type II is a heterodimeric signaling complex consisting of the Interleukin-22 receptor subunit alpha-1 (IL-22RA1) and the Interleukin-20 receptor subunit beta (IL-20RB) [PMID: 11533006]. It is a member of the type II cytokine receptor family and serves as a high-affinity receptor for the cytokines IL-20 and IL-24 [PMID: 11929860]. Upon binding of these ligands, the receptor recruits and activates Janus kinases (JAK1 and Tyk2), which subsequently phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) [PMID: 15123770]. This signaling pathway is primarily active in non-hematopoietic cells such as keratinocytes, bronchial epithelial cells, and synovial fibroblasts, where it promotes cell proliferation and the production of pro-inflammatory mediators [PMID: 22416238]. Dysregulation of the IL-20 receptor type II pathway is strongly associated with the pathogenesis of chronic inflammatory diseases, most notably psoriasis, where it drives epidermal thickening and inflammation [PMID: 12483210]. Therapeutic strategies targeting this receptor system include monoclonal antibodies designed to neutralize the ligands or block the receptor subunits to treat autoimmune and inflammatory conditions [PMID: 25130605].

Other names

IL-22RA1/IL-20RB complexIL-22R1/IL-20R2 heterodimerInterleukin-20 receptor type 2IL-20R type IIIL-20R2

Neutralization of IL-20 and IL-24 cytokines to prevent their binding to the IL-20 receptor type II complex, thereby inhibiting downstream JAK/STAT3 signaling and reducing inflammatory gene expression.